

Philip Livingston and Friedhelm Hellung
U.S. Serial No.: 08/196,154
Filed: June 7, 1995
Page 3

--45. (New) A vaccine that effectively treats cancer by stimulating or enhancing in a subject who is afflicted with cancer, production of an antibody which recognizes a ganglioside, comprising an amount of a ganglioside or an oligosaccharide portion thereof conjugated to an immunogenic protein effective to stimulate or enhance antibody production in the subject, an effective amount of adjuvant and a pharmaceutically acceptable vehicle.--

--46. (New) The vaccine of claim 44, wherein cells of the cancer have gangliosides on surfaces of cancerous cells.--

--47. (New) The vaccine of claim 44, wherein gangliosides are found in the stroma of the cancer.--

--48. (New) The vaccine of claim 44, wherein the cancer originates in epithelium.--

49
--49. (New) The vaccine of claim 45, wherein gangliosides are found in the stroma of the cancer.--

--50. (New) The vaccine of claim 45, wherein the cancer originates from epithelium.--

--51. (New) The vaccine of claim 44, wherein the cancer originates from neuroectoderm.--

--52. (New) The vaccine of claim 45, wherein the cancer originates from neuroectoderm.--

--53. (New) The vaccine of claim 49, wherein the cancer is a melanoma.--

--54. (New) The vaccine of claim 52, wherein the cancer is a melanoma.--

--55. (New) A method for stimulating or enhancing in a subject production of antibodies which recognize a ganglioside comprising administrating to the subject an effective dose of a vaccine comprising an amount of a ganglioside or oligosaccharide portion thereof conjugated to an immunogenic protein and an effective amount of adjuvant effective to stimulate or enhance antibody production in the subject.--

--56. (New) The method of claim 55, wherein the ganglioside is GM2. --

--57. (New) The method of claim 55, wherein the ganglioside is GD3. --

--58. (New) A method for treating cancer in a subject afflicted with cancer comprising administering to the subject an effective dose of the vaccine of claim 45. --

--59. (New) A method for preventing cancer in a subject susceptible to cancer comprising administering to the subject an effective dose of the vaccine of claim 44. --

--60. (New) The method of claim 55, 58 or 59, wherein the vaccine comprises a ganglioside or oligosaccharide portion thereof is conjugated to Keyhole Limpet Hemocyanin or a derivative or Keyhole Limpet Hemocyanin and an adjuvant. --

Philip Livingston and Friedhelm Hellung
U.S. Serial No.: 08/196,154
Filed: June 7, 1995
Page 5

--61. (New) The method of claim 60, wherein the adjuvant is QS-21.--

--62. (New) The method of claim 58 or 59, wherein the gangliosides are found on cancer cell surfaces.--

--63. (New) The method of claim 58 or 59, wherein the gangliosides are found in the stroma of the cancer. --
C

--64. (New) The method of claim 58 or 59, wherein the cancer originates from epithelium.--

--65. (New) The method of claim 58 or 59, wherein the cancer originates from neuroectoderm.--
*B
could*

--66. (New) The method of claim 65, wherein the cancer is a melanoma.--

--67. (New) The method of claim 55, wherein the administering comprises administering at two or more sites.--

--68. (New) The method of claim 67, wherein the administering comprises administering at three sites.--

REMARKS

Claims 21-43 were pending in the subject application. With the amendments hereinabove, applicants canceled claims 21-43 without prejudice to applicants' right to pursue the subject matter of these claims in a divisional or continuation application. Applicants added new claims 44-68. Accordingly,